Occam Places CSO of ADC Biotech MBrace Therapeutics
In March 2024, Occam recruited Steve Alley, PhD, as Chief Scientific Officer for MBrace Therapeutics, a Venrock, TPG, and Cowen investment.
Alley joins MBrace Therapeutics after serving as the Executive Director of Translational Sciences at Seagen. During his tenure at Seagen, Alley played a crucial role in the company's rapid growth by assuming various leadership positions in research and development. Alley led the bioanalysis and DMPK groups, contributed to developing Seagen's ADC technology platform, and led the cross-functional team that discovered the Seagen Sugar Engineered Antibody technology platform.
MBrace was founded in 2020 by CEO Isan Chen, M.D.,formerly CMO of Mirati Therapeutics; Renata Pasqualini, Ph.D.; and Wadih Arap, M.D./Ph.D. MBrace is a clinical-stage biopharmaceutical company developing innovative ADC cancer therapeutics utilizing the SPARTA technology pioneered by its founders.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.